Dimensional Fund Advisors LP Sells 127,664 Shares of Janux Therapeutics, Inc. $JANX

Dimensional Fund Advisors LP trimmed its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 56.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 96,630 shares of the company’s stock after selling 127,664 shares during the period. Dimensional Fund Advisors LP’s holdings in Janux Therapeutics were worth $1,343,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Janux Therapeutics in the fourth quarter worth $34,000. Osaic Holdings Inc. lifted its stake in Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after acquiring an additional 3,037 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Janux Therapeutics during the 4th quarter valued at about $51,000. Tower Research Capital LLC TRC boosted its holdings in shares of Janux Therapeutics by 175.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after acquiring an additional 2,502 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Janux Therapeutics by 185.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,673 shares of the company’s stock valued at $177,000 after acquiring an additional 4,982 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Insider Activity

In related news, insider Janeen Noel Doyle sold 4,059 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total transaction of $56,947.77. Following the completion of the transaction, the insider owned 75,941 shares in the company, valued at $1,065,452.23. The trade was a 5.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 7.90% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on JANX. Evercore set a $22.00 price objective on shares of Janux Therapeutics in a report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a report on Monday, July 20th. Wedbush decreased their target price on shares of Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, May 8th. Stifel Nicolaus set a $35.00 price target on Janux Therapeutics in a report on Friday, August 7th. Finally, Piper Sandler dropped their price target on Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Janux Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.58.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $16.12 on Friday. The company has a market cap of $985.58 million, a P/E ratio of -9.83 and a beta of 2.50. The business’s 50 day moving average price is $15.30 and its 200-day moving average price is $14.53. Janux Therapeutics, Inc. has a fifty-two week low of $12.12 and a fifty-two week high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The company had revenue of $10.27 million during the quarter, compared to the consensus estimate of $19.07 million. As a group, equities analysts predict that Janux Therapeutics, Inc. will post -1.76 EPS for the current year.

Janux Therapeutics Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.